Search
Structure Therapeutics Inc
GPCRAdd to Watchlist
44.510USD
-0.490-1.09%
Close 06/18, 16:00（ET）Quotes delayed by 15 min
3.16BMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated:Analyst Rating
Based on
18
analysts
Buy
Current Rating
106.533
Target Price
+139.35%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
560
Total
5
Median
6
Average
Company name
Ratings
Analysts
Structure Therapeutics Inc
GPCR
18
Ionis Pharmaceuticals Inc
IONS
27
Beigene Ltd
ONC
27
CRISPR Therapeutics AG
CRSP
27
IQVIA Holdings Inc
IQV
26
argenx SE
ARGX
26
1
2
3
...
112
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is Structure Therapeutics Inc's price target?
Analysts forecast that Structure Therapeutics Inc's price target is USD 65.00, with the highest forecast at USD 120.00 and the lowest forecast at USD 50.00.
How have Structure Therapeutics IncGPCR's recent earnings per share performed?
The market expectation was USD -1.05, while Structure Therapeutics IncGPCR's earnings per share (EPS) for the previous quarter was USD 0.52. EPS for the next quarter is expected at USD -0.39.
What is the analyst rating for Structure Therapeutics Inc?
Based on the ratings of Structure Therapeutics Inc's stock from 18 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
